IL6 and COVID-19: A second hypothesis is an increased peripheral blood frequency of a subset of polyclonal GM-CSF+ CD4 T cells capable of prodigious ex-vivo IL-6 and IFN-γ production, which has been described in COVID-19, although only in critically ill patients (58).